A disruption in the production of NO is a problem that causes persistent vasoconstriction and represents the rationale for the use of drugs targeting the NO-sGC-cGMP pathway for treating patients with COPD-associated PH. The gene discussed is SGCB; the disease is chronic obstructive pulmonary disease.